Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia.
To find the clinical variables associated with atorvastatin's effects on bone metabolism markers, 35 patients with heterozygous familial hypercholesterolemia were treated with atorvastatin for 24 weeks, and the levels of bone formation markers (bone-specific alkaline phosphatase and osteocalcin) and resorption marker (urine collagen type-1 cross-linked N-telopeptide) were determined. Pretreatment vitamin D levels showed significant and positive associations with changes in 2 bone formation markers. The serial changes in 3 markers were favorable-increased bone formation markers and unchanged bone resorption marker-but the changes occurred only in patients with pretreatment vitamin D levels >50 pg/ml.
Kajinami
Kouji
K
Department of Cardiology, Kanazawa Medical University, Daigaku, Uchinada-machi, Japan. kajinami@kanazawa-med.ac.jp
Takekoshi
Noboru
N
Matsui
Shinobu
S
Kanemitsu
Seiyu
S
Okubo
Shinji
S
Kanayama
Sugako
S
Yamashita
Naohiro
N
Sato
Ryoko
R
D000328:Adult; D000368:Aged; D000069059:Atorvastatin; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D006579:Heterozygote; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006938:Hyperlipoproteinemia Type II / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010012:Osteogenesis / Q000187:drug effects*; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D014807:Vitamin D / Q000097:blood*
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D014807:Vitamin D; D000069059:Atorvastatin